# EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma

> **NCT01000285** · PHASE1,PHASE2 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 18 (actual)

## Conditions studied

- Leukemia-Lymphoma, Adult T-Cell

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Etoposide
- **DRUG:** Vincristine
- **DRUG:** Doxorubicin
- **DRUG:** Prednisone
- **DRUG:** Cyclophosphamide
- **DRUG:** Raltegravir

## Key facts

- **NCT ID:** NCT01000285
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2014-05
- **Final completion:** 2016-04
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2017-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01000285

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01000285, "EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01000285. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*